PMA supplement
P180038 S006: LIAISON® XL MUREX Anti-HBc and LIAISON® XL MUREX Control Anti-HBC
FDA PMA supplement · Real-Time Process · DiaSorin, Inc.
Key facts
| Original PMA | P180038 |
|---|---|
| Supplement number | S006 |
| Supplement type | Real-Time Process |
| Reason for the supplement | Change Design/Components/Specifications/Material |
| Trade name | LIAISON® XL MUREX Anti-HBc and LIAISON® XL MUREX Control Anti-HBC |
| Generic name | Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) |
| Applicant | DiaSorin, Inc. |
| Product code | LOM |
| Received date | Nov 19, 2021 |
| Decision date | Jan 21, 2022 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: